Xilio Therapeutics, Inc. (XLO) intrinsic value & 10-year financials
Xilio Therapeutics, Inc. (XLO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 589.9% a year to $43.8M, with an average return on invested capital of 993.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $8.55
- Market cap
- $71.5M
- Revenue (FY2025)
- $43.8M
- Revenue growth (7-yr CAGR)
- 589.9%
- ROIC (10-yr avg)
- 993.4%
- Free cash flow (FY2025)
- -$5.5M
XLO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $43.8M | -$35.0M | -$4.19 | -$5.5M | -95.9% | 65.9% |
| FY2024 | $6.3M | -$58.2M | -$1.09 | -$18.4M | -954.9% | 397.6% |
| FY2023 | — | -$76.4M | -$2.78 | -$69.1M | — | 3020.9% |
| FY2022 | — | -$88.2M | -$3.22 | -$77.6M | — | 2256.1% |
| FY2021 | — | -$75.8M | -$13.52 | -$81.9M | — | 160.0% |
| FY2020 | — | -$55.2M | -$105.42 | -$38.3M | — | 59.7% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Xilio Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Xilio Therapeutics, Inc. has earned high returns on invested capital, averaging 30.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Xilio Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Xilio Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-139.17 per share.